DunPort supports MML’s investment in Innopharma
DunPort are delighted to announce that we have supported MML Ireland’s investment in Innopharma. MML have invested in the business alongside the management team and founder shareholder, Dr. Ian Jones, in support of their ambitious growth plans.
Innopharma is Ireland’s leading provider of higher and further education, focused on up-skilling and re-skilling individuals to enter or progress within the pharmaceutical, medtech and food & beverage manufacturing sectors. It is also a provider of highly trained, contract technical resources to client companies within the pharmaceutical and medtech industries. Innopharma is the largest private life science higher education institution in Ireland with courses being delivered nationwide across Dublin, Cork, Limerick and Galway. It is headquartered in Sandyford, Dublin and employs 130 people. The business expects to deliver revenue of c. €15 million across its two divisions, Education and Technical Services, in the year to 30 June 2023.
Mazars Corporate Finance provided corporate finance advice to the shareholders of Innopharma. McCann Fitzgerald acted as legal adviser to MML Ireland, while Philip Lee acted for Innopharma. BDO provided financial and tax due diligence whilst KPMG carried out a commercial and strategic review for the Group. DunPort were also advised by McCann Fitzgerald.
Innopharma is the 11th company to have been supported by the Oak Corporate Credit Fund, DunPort’s €335m direct lending vehicle, and the 56th unique company which DunPort has supported overall. DunPort is one of the leading providers of SME and Corporate private debt solutions in both Ireland and the UK’s lower mid-market and has more recently entered the Benelux market.
The investment is subject to approval from the Competition and Consumer Protection Commission (CCPC).
